Bi-Coastal Pharma International

Form 483 issued January 14, 2022 · Shrewsbury, New Jersey

Inspection
Dec 15, 2021 – Jan 14, 2022
Observations
5
Pages
8
FEI number
3013263547

In short: On January 14, 2022, FDA issued a Form 483 with 5 observations to Bi-Coastal Pharma International in Shrewsbury, New Jersey (FEI 3013263547) after an inspection that ran Dec 15, 2021 – Jan 14, 2022. The investigators were Guerlain Ulysse and Rose Jean-Mary. Most observations concern quality system and laboratory controls; the most-cited regulation is 21 CFR 211.198 (complaint files).

At a glance

4 of 5 observations on this 483 concern quality system.

Quality system4
Laboratory controls1

What FDA observed

Preview: the opening words of each observation
  1. 01

    The responsibilities and procedures applicable to the quality control unit are not in…

  2. 02

    There is no written testing program designed to assess the stability…

  3. 03

    Complaint records are deficient in that they do not include the findings of the…

  4. 04

    Procedures describing the handling of written and oral complaints related to drug products are…

1 more observation

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Bi-Coastal Pharma International?

FDA listed 5 observations on this Form 483, mostly about quality system and laboratory controls. The most-cited regulation is 21 CFR 211.198 (complaint files). The opening words of each observation are shown on this page.

Who inspected Bi-Coastal Pharma International?

Guerlain Ulysse and Rose Jean-Mary are named on this Form 483, for the inspection of Dec 15, 2021 – Jan 14, 2022. Each investigator has a profile showing what they cite most.

When was Bi-Coastal Pharma International inspected by FDA?

The inspection ran Dec 15, 2021 – Jan 14, 2022, and the Form 483 is dated January 14, 2022.

How do I get the full Form 483 for Bi-Coastal Pharma International?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free